[S02DA03, antipyrine, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Antipyrine.]
[B01AD01, streptokinase, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Streptokinase.]
[J01GA01, streptomycin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Streptomycin.]
[M03AB01, succinylcholine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Mesalazine.]
[A02BX02, sucralfate, Mesalazine may decrease the excretion rate of Sucralfate which could result in a higher serum level.]
[J01CG01, sulbactam, Mesalazine may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, Mesalazine may increase the hypoglycemic activities of Sulfadiazine.]
[J01EC01, sulfamethoxazole, Mesalazine may increase the hypoglycemic activities of Sulfamethoxazole.]
[M04AB02, sulfinpyrazone, The risk or severity of bleeding can be increased when Mesalazine is combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, Mesalazine may increase the hypoglycemic activities of Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Sulindac.]
[M01AE07, suprofen, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Suprofen.]
[A10BB04, glibornuride, Mesalazine may increase the hypoglycemic activities of Glibornuride.]
[A10BC01, glymidine, Mesalazine may increase the hypoglycemic activities of Glymidine.]
[M01AX04, apazone, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Azapropazone.]
[L01BB02, mercaptopurine, The risk or severity of myelosuppression can be increased when Mesalazine is combined with Mercaptopurine.]
[N05CD07, temazepam, Mesalazine may decrease the excretion rate of Temazepam which could result in a higher serum level.]
[R03CC03, terbutaline, The risk or severity of hypertension can be increased when Mesalazine is combined with Terbutaline.]
[B01AE07, dabigatran etexilate, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Dabigatran etexilate.]
[G03BA03, testosterone, Mesalazine may decrease the excretion rate of Testosterone which could result in a higher serum level.]
[S03AA02, tetracycline, Mesalazine may decrease the excretion rate of Tetracycline which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Ceftaroline fosamil.]
[N05AE05, lurasidone, The risk or severity of hypertension can be increased when Mesalazine is combined with Lurasidone.]
[P02CA02, thiabendazole, Mesalazine may decrease the excretion rate of Thiabendazole which could result in a higher serum level.]
[R06AD03, thiethylperazine, Mesalazine may decrease the excretion rate of Thiethylperazine which could result in a higher serum level.]
[L01BB03, thioguanine, The metabolism of Tioguanine can be decreased when combined with Mesalazine.]
[N05AB08, thioproperazine, The risk or severity of hypertension can be increased when Mesalazine is combined with Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of hypertension can be increased when Mesalazine is combined with Thioridazine.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Mesalazine is combined with Moxisylyte.]
[N05AL03, tiapride, Mesalazine may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[B01AC05, ticlopidine, The risk or severity of bleeding can be increased when Mesalazine is combined with Ticlopidine.]
[S01ED01, timolol, Mesalazine may decrease the antihypertensive activities of Timolol.]
[P01AB02, tinidazole, Mesalazine may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[S01AA12, tobramycin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Tobramycin.]
[A10BB05, tolazamide, Mesalazine may increase the hypoglycemic activities of Tolazamide.]
[M02AX02, tolazoline, The therapeutic efficacy of Tolazoline can be decreased when used in combination with Mesalazine.]
[V04CA01, tolbutamide, Mesalazine may increase the hypoglycemic activities of Tolbutamide.]
[M02AA21, tolmetin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Tolmetin.]
[N02AX02, tramadol, Mesalazine may decrease the excretion rate of Tramadol which could result in a higher serum level.]
[N06AF04, tranylcypromine, The risk or severity of hypertension can be increased when Mesalazine is combined with Tranylcypromine.]
[C01DX11, trapidil, The risk or severity of bleeding can be increased when Mesalazine is combined with Trapidil.]
[N06AX05, trazodone, The risk or severity of gastrointestinal bleeding can be increased when Trazodone is combined with Mesalazine.]
[S01BA05, triamcinolone, The risk or severity of gastrointestinal irritation can be increased when Triamcinolone is combined with Mesalazine.]
[C03DB02, triamterene, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Triamterene.]
[N05CD05, triazolam, Mesalazine may decrease the excretion rate of Triazolam which could result in a higher serum level.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mesalazine.]
[A16AX12, trientine, Mesalazine may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, The risk or severity of hypertension can be increased when Mesalazine is combined with Trifluoperazine.]
[S01AD02, trifluridine, Mesalazine may decrease the excretion rate of Trifluridine which could result in a higher serum level.]
[D07AC02, fluclorolone, The risk or severity of gastrointestinal irritation can be increased when Fluclorolone is combined with Mesalazine.]
[R03BA07, mometasone, The risk or severity of gastrointestinal irritation can be increased when Mometasone is combined with Mesalazine.]
[A03AA05, trimebutine, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Trimebutine.]
[N03AC02, trimethadione, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Trimethadione.]
[C02BA01, trimethaphan, The therapeutic efficacy of Trimethaphan can be decreased when used in combination with Mesalazine.]
[J01EA01, trimethoprim, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Trimethoprim.]
[N06AA06, trimipramine, The risk or severity of gastrointestinal bleeding can be increased when Trimipramine is combined with Mesalazine.]
[N06AX24, vilazodone, The risk or severity of hypertension can be increased when Mesalazine is combined with Vilazodone.]
[C09CA09, azilsartan medoxomil, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azilsartan medoxomil is combined with Mesalazine.]
[R03DX07, roflumilast, Mesalazine may decrease the excretion rate of Roflumilast which could result in a higher serum level.]
[L01FX04, ipilimumab, Mesalazine may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[R02AA14, oxyquinoline, Mesalazine may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[A10BH05, linagliptin, Mesalazine may increase the hypoglycemic activities of Linagliptin.]
[J05AP02, telaprevir, The excretion of Mesalazine can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The excretion of Mesalazine can be decreased when combined with Rilpivirine.]
[B01AD04, urokinase, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Urokinase.]
[S01AA28, vancomycin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Vancomycin.]
[N03AX21, ezogabine, Mesalazine may decrease the excretion rate of Ezogabine which could result in a higher serum level.]
[B01AF01, rivaroxaban, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Rivaroxaban.]
[R03AC18, indacaterol, The risk or severity of hypertension can be increased when Mesalazine is combined with Indacaterol.]
[B01AC24, ticagrelor, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Ticagrelor.]
[C08DA01, verapamil, The risk or severity of bleeding can be increased when Verapamil is combined with Mesalazine.]
[N06AX09, viloxazine, Mesalazine may decrease the excretion rate of Viloxazine which could result in a higher serum level.]
[L01CA01, vinblastine, The excretion of Mesalazine can be decreased when combined with Vinblastine.]
[C04AX07, vincamine, The therapeutic efficacy of Vincamine can be decreased when used in combination with Mesalazine.]
[L01CA02, vincristine, The excretion of Mesalazine can be decreased when combined with Vincristine.]
[B03BA01, vitamin B12, Mesalazine may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level.]
[B01AA03, warfarin, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Warfarin.]
[S01AA13, fusidic acid, The excretion of Mesalazine can be decreased when combined with Fusidic acid.]
[N01AX15, xenon, The risk or severity of hypertension can be increased when Mesalazine is combined with Xenon.]
[C03BA10, xipamide, The therapeutic efficacy of Xipamide can be decreased when used in combination with Mesalazine.]
[J05AF01, zidovudine, The risk or severity of bleeding can be increased when Zidovudine is combined with Mesalazine.]
[N05AF05, zuclopenthixol, The risk or severity of hypertension can be increased when Mesalazine is combined with Zuclopenthixol.]
[J05AE02, indinavir, The excretion of Mesalazine can be decreased when combined with Indinavir.]
[M05BA03, pamidronic acid, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Pamidronic acid.]
[M05BA05, tiludronic acid, The risk or severity of gastrointestinal bleeding can be increased when Mesalazine is combined with Tiludronic acid.]
[B06AC02, icatibant, Mesalazine may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[B01AE01, desirudin, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Lepirudin.]
[A02BC04, rabeprazole, Rabeprazole can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M05BA06, ibandronic acid, The risk or severity of gastrointestinal bleeding can be increased when Mesalazine is combined with Ibandronate.]
[J01MA13, trovafloxacin, Mesalazine may increase the neuroexcitatory activities of Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of hypertension can be increased when Mesalazine is combined with Ziprasidone.]
[G03AC10, drospirenone, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Drospirenone.]
[V03AC02, deferiprone, Mesalazine may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, Mesalazine may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, Mesalazine may decrease the excretion rate of Tolterodine which could result in a higher serum level.]
[J01DH04, doripenem, Mesalazine may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, Mesalazine may decrease the antihypertensive activities of Atenolol.]
[J02AC03, voriconazole, The serum concentration of Mesalazine can be increased when it is combined with Voriconazole.]
[S01FA01, atropine, The risk or severity of hypertension can be increased when Mesalazine is combined with Atropine.]
[M01CB03, auranofin, Mesalazine may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[L01EK01, axitinib, The excretion of Mesalazine can be decreased when combined with Axitinib.]
[S01EE05, tafluprost, The therapeutic efficacy of Tafluprost can be decreased when used in combination with Mesalazine.]
[H02AB11, prednylidene, The risk or severity of gastrointestinal irritation can be increased when Prednylidene is combined with Mesalazine.]
[B03XA04, peginesatide, Mesalazine may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Mesalazine may decrease the excretion rate of Azacitidine which could result in a higher serum level.]
[L04AX01, azathioprine, The risk or severity of myelosuppression can be increased when Mesalazine is combined with Azathioprine.]
[L01BC05, gemcitabine, Mesalazine may decrease the excretion rate of Gemcitabine which could result in a higher serum level.]
[J01DF01, aztreonam, Mesalazine may decrease the excretion rate of Aztreonam which could result in a higher serum level.]
[R02AB04, bacitracin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Bacitracin.]
[M03BX01, baclofen, Mesalazine may decrease the excretion rate of Baclofen which could result in a higher serum level.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The risk or severity of adverse effects can be increased when Mesalazine is combined with Varicella zoster vaccine (live/attenuated).]
[A08AA11, lorcaserin, Mesalazine may decrease the excretion rate of Lorcaserin which could result in a higher serum level.]
[G04BD12, mirabegron, The risk or severity of hypertension can be increased when Mesalazine is combined with Mirabegron.]
[V03AX03, cobicistat, The excretion of Mesalazine can be decreased when combined with Cobicistat.]
[L02BB04, enzalutamide, Mesalazine may decrease the excretion rate of Enzalutamide which could result in a higher serum level.]
[L04AA31, teriflunomide, The excretion of Mesalazine can be decreased when combined with Teriflunomide.]
[A02AA05, magnesium silicate, Magnesium silicate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B01AX01, defibrotide, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Defibrotide.]
[C01CA18, octopamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Octopamine.]
[A02AC02, calcium silicate, Calcium silicate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AA01, aldosterone, The risk or severity of gastrointestinal irritation can be increased when Aldosterone is combined with Mesalazine.]
[C01AA01, acetyldigitoxin, The serum concentration of Acetyldigitoxin can be decreased when it is combined with Mesalazine.]
[D02BA02, octinoxate, Mesalazine may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The excretion of Mesalazine can be decreased when combined with Nelfinavir.]
[N04BD02, rasagiline, The risk or severity of hypertension can be increased when Mesalazine is combined with Rasagiline.]
[C08CA13, lercanidipine, The therapeutic efficacy of Lercanidipine can be decreased when used in combination with Mesalazine.]
[N02CC03, zolmitriptan, The risk or severity of hypertension can be increased when Mesalazine is combined with Zolmitriptan.]
[V09IX04, fluorodeoxyglucose F18, Mesalazine may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, The risk or severity of hypertension can be increased when Mesalazine is combined with Diethyl ether.]
[G04BE03, sildenafil, The excretion of Mesalazine can be decreased when combined with Sildenafil.]
[V08CA11, gadofosveset, Mesalazine may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[B01AF02, apixaban, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Apixaban.]
[A16AX08, teduglutide, Mesalazine may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[C04AX11, bencyclane, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Bencyclane.]
[A10BH04, alogliptin, Mesalazine may increase the hypoglycemic activities of Alogliptin.]
[A16AX09, glycerol phenylbutyrate, Mesalazine may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mesalazine.]
[L04AX06, pomalidomide, Mesalazine may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N02BA10, benorilate, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Benorilate.]
[A10BK02, canagliflozin, Mesalazine may increase the hypoglycemic activities of Canagliflozin.]
[J01MA15, gemifloxacin, Mesalazine may increase the neuroexcitatory activities of Gemifloxacin.]
[M04AB03, benzbromarone, The excretion of Mesalazine can be decreased when combined with Benzbromarone.]
[S01AE07, moxifloxacin, Mesalazine may increase the neuroexcitatory activities of Moxifloxacin.]
[H03AA04, tiratricol, The therapeutic efficacy of Tiratricol can be increased when used in combination with Mesalazine.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Mesalazine is combined with Insulin detemir.]
[A10BX05, pramlintide, Mesalazine may increase the hypoglycemic activities of Pramlintide.]
[J02AX04, caspofungin, The excretion of Mesalazine can be decreased when combined with Caspofungin.]
[L03AA12, ancestim, Mesalazine may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Celecoxib.]
[N02CC02, naratriptan, The risk or severity of hypertension can be increased when Mesalazine is combined with Naratriptan.]
[C10AC04, colesevelam, Colesevelam can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AA18, everolimus, The excretion of Mesalazine can be decreased when combined with Everolimus.]
[N04AC01, benztropine, Mesalazine may decrease the excretion rate of Benzatropine which could result in a higher serum level.]
[L01EC02, dabrafenib, The excretion of Mesalazine can be decreased when combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Benzydamine.]
[L01EE01, trametinib, Mesalazine may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[V09AX05, florbetapir F-18, Mesalazine may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, The risk or severity of gastrointestinal bleeding can be increased when Levomilnacipran is combined with Mesalazine.]
[C08EA02, bepridil, The therapeutic efficacy of Bepridil can be decreased when used in combination with Mesalazine.]
[C02KX05, riociguat, The therapeutic efficacy of Riociguat can be decreased when used in combination with Mesalazine.]
[A10BJ03, lixisenatide, Mesalazine may increase the hypoglycemic activities of Lixisenatide.]
[A05AA03, cholic acid, The excretion of Mesalazine can be increased when combined with Cholic Acid.]
[C02KX04, macitentan, The therapeutic efficacy of Macitentan can be decreased when used in combination with Mesalazine.]
[N06AX26, vortioxetine, The risk or severity of hypertension can be increased when Mesalazine is combined with Vortioxetine.]
[G03AC08, etonogestrel, Mesalazine may decrease the excretion rate of Etonogestrel which could result in a higher serum level.]
[J05AP05, simeprevir, The excretion of Mesalazine can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, Mesalazine may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[A10BK01, dapagliflozin, Mesalazine may increase the hypoglycemic activities of Dapagliflozin.]
[C01CA27, droxidopa, The risk or severity of hypertension can be increased when Mesalazine is combined with Droxidopa.]
[C07AB04, acebutolol, Mesalazine may decrease the antihypertensive activities of Acebutolol.]
[N05CH03, tasimelteon, Mesalazine may decrease the excretion rate of Tasimelteon which could result in a higher serum level.]
[L04AA32, apremilast, Mesalazine may decrease the excretion rate of Apremilast which could result in a higher serum level.]
[L02BG02, formestane, Mesalazine may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S03BA03, betamethasone, The risk or severity of gastrointestinal irritation can be increased when Betamethasone is combined with Mesalazine.]
[S01ED02, betaxolol, Mesalazine may decrease the antihypertensive activities of Betaxolol.]
[B01AE03, argatroban, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Argatroban.]
[V03AB34, fomepizole, Mesalazine may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C02CC01, bethanidine, The therapeutic efficacy of Bethanidine can be decreased when used in combination with Mesalazine.]
[C10AB02, bezafibrate, The excretion of Mesalazine can be decreased when combined with Bezafibrate.]
[A10BJ04, albiglutide, Mesalazine may increase the hypoglycemic activities of Albiglutide.]
[B01AC26, vorapaxar, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Vorapaxar.]
[B01AA07, acenocoumarol, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Acenocoumarol.]
[L01EM01, idelalisib, The excretion of Mesalazine can be decreased when combined with Idelalisib.]
[A10BK03, empagliflozin, Mesalazine may increase the hypoglycemic activities of Empagliflozin.]
[R03AC19, olodaterol, The risk or severity of hypertension can be increased when Mesalazine is combined with Olodaterol.]
[V08AA01, diatrizoic acid, Mesalazine may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[S01EE02, unoprostone, The therapeutic efficacy of Unoprostone can be decreased when used in combination with Mesalazine.]
[V08AA04, iothalamic acid, Mesalazine may decrease the excretion rate of Diatrizoate which could result in a higher serum level.]
[S01AA15, dihydrostreptomycin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Dihydrostreptomycin.]
[N05AA04, acepromazine, The risk or severity of hypertension can be increased when Mesalazine is combined with Acepromazine.]
[A10BJ05, dulaglutide, Mesalazine may increase the hypoglycemic activities of Dulaglutide.]
[S03AA06, gentamicin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Gentamicin.]
[B01AA01, dicumarol, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Dicoumarol.]
[B01AF03, edoxaban, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Edoxaban.]
[N06AX11, mirtazapine, The risk or severity of hypertension can be increased when Mesalazine is combined with Mirtazapine.]
[L01EX08, lenvatinib, The excretion of Mesalazine can be decreased when combined with Lenvatinib.]
[J05AP07, daclatasvir, The excretion of Mesalazine can be decreased when combined with Daclatasvir.]
[N02BE01, acetaminophen, The risk or severity of adverse effects can be increased when Acetaminophen is combined with Mesalazine.]
[L01DC01, bleomycin, Mesalazine may decrease the excretion rate of Bleomycin which could result in a higher serum level.]
[B01AA11, tioclomarol, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Tioclomarol.]
[J05AF08, adefovir dipivoxil, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Adefovir dipivoxil.]
[J05AP06, asunaprevir, The excretion of Mesalazine can be decreased when combined with Asunaprevir.]
[A07DA06, eluxadoline, The excretion of Mesalazine can be decreased when combined with Eluxadoline.]
[B01AC25, cangrelor, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Cangrelor.]
[N05AX16, brexpiprazole, The risk or severity of hypertension can be increased when Mesalazine is combined with Brexpiprazole.]
[G02CX02, flibanserin, The risk or severity of hypertension can be increased when Mesalazine is combined with Flibanserin.]
[A06AD03, magnesium peroxide, Magnesium peroxide can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05AX15, cariprazine, The risk or severity of hypertension can be increased when Mesalazine is combined with Cariprazine.]
[A10BF01, acarbose, Mesalazine may increase the hypoglycemic activities of Acarbose.]
[M02AA25, aceclofenac, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Mesalazine is combined with Acetazolamide.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Mesalazine is combined with Insulin degludec.]
[A02BC03, lansoprazole, Lansoprazole can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AB37, idarucizumab, Mesalazine may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[J05AF13, tenofovir alafenamide, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Tenofovir alafenamide.]
[L01EE02, cobimetinib, The excretion of Mesalazine can be decreased when combined with Cobimetinib.]
[L01XG03, ixazomib, Mesalazine may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[B01AC27, selexipag, The therapeutic efficacy of Selexipag can be decreased when used in combination with Mesalazine.]
[A10BB31, acetohexamide, Mesalazine may increase the hypoglycemic activities of Acetohexamide.]
[M04AB05, lesinurad, Mesalazine may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[M01AE16, alminoprofen, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Alminoprofen.]
[A02AB06, aloglutamol, Aloglutamol can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N02BA02, aloxiprin, The therapeutic efficacy of Aloxiprin can be decreased when used in combination with Mesalazine.]
[N03AX23, brivaracetam, Mesalazine may decrease the excretion rate of Brivaracetam which could result in a higher serum level.]
[L01XX52, venetoclax, The excretion of Mesalazine can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, Mesalazine may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[N04BC01, bromocriptine, Mesalazine may increase the hypoglycemic activities of Bromocriptine.]
[A02AD05, aluminum magnesium silicate, Almasilate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AB03, aluminum phosphate, Aluminium phosphate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06AA19, amineptin, The risk or severity of gastrointestinal bleeding can be increased when Amineptine is combined with Mesalazine.]
[C08CA01, amlodipine, Mesalazine may decrease the antihypertensive activities of Amlodipine.]
[M02AA09, bufexamac, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Bufexamac.]
[C03CA02, bumetanide, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Bumetanide.]
[N01BB01, bupivacaine, Mesalazine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[C07AA19, bupranolol, Mesalazine may decrease the antihypertensive activities of Bupranolol.]
[N05BE01, buspirone, The risk or severity of hypertension can be increased when Mesalazine is combined with Buspirone.]
[L01XX27, arsenic trioxide, Mesalazine may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[M02AA03, clofezone, Rabeprazole can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01MA09, sparfloxacin, Mesalazine may increase the neuroexcitatory activities of Sparfloxacin.]
[A07EC04, balsalazide, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Balsalazide.]
[R03CC12, bambuterol, The risk or severity of hypertension can be increased when Mesalazine is combined with Bambuterol.]
[A06AH05, naldemedine, Mesalazine may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Mesalazine may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, Mesalazine may decrease the excretion rate of Pregabalin which could result in a higher serum level.]
[C09AA07, benazepril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Benazepril.]
[A10BX06, benfluorex, Mesalazine may increase the hypoglycemic activities of Benfluorex.]
[A12AA04, calcium carbonate, Calcium carbonate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[P01CA02, benznidazole, Mesalazine may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, The risk or severity of hypertension can be increased when Mesalazine is combined with Linezolid.]
[J05AF06, abacavir, Mesalazine may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[J05AE09, tipranavir, The excretion of Mesalazine can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, Mesalazine may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[N04BD03, safinamide, The risk or severity of hypertension can be increased when Mesalazine is combined with Safinamide.]
[J01MA23, delafloxacin, Mesalazine may increase the neuroexcitatory activities of Delafloxacin.]
[B01AF04, betrixaban, The risk or severity of bleeding can be increased when Betrixaban is combined with Mesalazine.]
[L01BC06, capecitabine, Mesalazine may decrease the excretion rate of Capecitabine which could result in a higher serum level.]
[L01XX59, enasidenib, The excretion of Mesalazine can be decreased when combined with Enasidenib.]
[A02BX12, bismuth subnitrate, Bismuth subnitrate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C07AB07, bisoprolol, Mesalazine may decrease the antihypertensive activities of Bisoprolol.]
[R03AC17, bitolterol, The risk or severity of hypertension can be increased when Mesalazine is combined with Bitolterol.]
[J01DC10, cefprozil, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefprozil.]
[C07AA17, bopindolol, Mesalazine may decrease the antihypertensive activities of Bopindolol.]
[V03AB23, acetylcysteine, The excretion of Mesalazine can be decreased when combined with Acetylcysteine.]
[S01BC11, bromfenac, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Bromfenac.]
[C03DA03, canrenone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Canrenone.]
[R03BA02, budesonide, The risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Mesalazine.]
[C04AX20, buflomedil, The risk or severity of bleeding can be increased when Mesalazine is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Bumadizone.]
[S01EE06, latanoprostene bunod, The therapeutic efficacy of Latanoprostene bunod can be decreased when used in combination with Mesalazine.]
[N06AA15, butriptyline, The risk or severity of gastrointestinal bleeding can be increased when Butriptyline is combined with Mesalazine.]
[C01AA02, acetyldigoxins, Mesalazine may decrease the excretion rate of Acetyldigoxin which could result in a higher serum level.]
[A10BJ06, semaglutide, Mesalazine may increase the hypoglycemic activities of Semaglutide.]
[A10BK04, ertugliflozin, Mesalazine may increase the hypoglycemic activities of Ertugliflozin.]
[R06AX18, acrivastine, Mesalazine may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[C09AA01, captopril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Captopril.]
[V04CD06, macimorelin, The therapeutic efficacy of Macimorelin can be decreased when used in combination with Mesalazine.]
[L02BB05, apalutamide, The excretion of Mesalazine can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, Mesalazine may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[C07AG02, carvedilol, Mesalazine may decrease the antihypertensive activities of Carvedilol.]
[N03AX24, cannabidiol, The risk or severity of hypertension can be increased when Mesalazine is combined with Cannabidiol.]
[L04AA37, baricitinib, Mesalazine may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[V03AE10, sodium zirconium cyclosilicate, Sodium zirconium cyclosilicate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01DE01, cefepime, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefepime.]
[J01DD10, cefetamet, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefetamet.]
[J01DD09, cefodizime, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefodizime.]
[J01DC11, ceforanide, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Ceforanide.]
[J01DD13, cefpodoxime, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefpodoxime.]
[J01DD14, ceftibuten, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Ceftibuten.]
[J01GB14, plazomicin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Plazomicin.]
[C07AB08, celiprolol, Mesalazine may decrease the antihypertensive activities of Celiprolol.]
[A16AX14, migalastat, Mesalazine may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, Mesalazine may decrease the excretion rate of Stiripentol which could result in a higher serum level.]
[S01GX12, cetirizine, Mesalazine may decrease the excretion rate of Cetirizine which could result in a higher serum level.]
[A10BB06, carbutamide, Mesalazine may increase the hypoglycemic activities of Carbutamide.]
[D08AE05, chloroxylenol, Mesalazine may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Lornoxicam.]
[N07XX15, inotersen, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Inotersen.]
[L01AD01, carmustine, Mesalazine may decrease the excretion rate of Carmustine which could result in a higher serum level.]
[A06AX05, prucalopride, Mesalazine may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[C09AA08, cilazapril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Cilazapril.]
[B01AX07, caplacizumab, The risk or severity of bleeding can be increased when Mesalazine is combined with Caplacizumab.]
[B01AC23, cilostazol, The risk or severity of bleeding can be increased when Mesalazine is combined with Cilostazol.]
[A03FA08, cinitapride, The risk or severity of hypertension can be increased when Mesalazine is combined with Cinitapride.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Mesalazine.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Mesalazine is combined with Siponimod.]
[J01FA09, clarithromycin, The excretion of Mesalazine can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Mesalazine.]
[N05BA09, clobazam, Mesalazine may decrease the excretion rate of Clobazam which could result in a higher serum level.]
[H02AB14, cloprednol, The risk or severity of gastrointestinal irritation can be increased when Cloprednol is combined with Mesalazine.]
[C09CA06, candesartan, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Candesartan is combined with Mesalazine.]
[V03AE02, sevelamer, Sevelamer can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AB17, cortivazol, The risk or severity of gastrointestinal irritation can be increased when Cortivazol is combined with Mesalazine.]
[J01DC04, cefaclor, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefaclor.]
[J01DB05, cefadroxil, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefadroxil.]
[J01DC03, cefamandole, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefamandole.]
[L01XX66, selinexor, The excretion of Mesalazine can be decreased when combined with Selinexor.]
[J01DB07, cefatrizine, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefatrizine.]
[J01DB04, cefazolin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefazolin.]
[L02BB06, darolutamide, The excretion of Mesalazine can be decreased when combined with Darolutamide.]
[J01DC09, cefmetazole, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefmetazole.]
[J01DC06, cefonicid, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefonicid.]
[L01EX15, pexidartinib, The excretion of Mesalazine can be decreased when combined with Pexidartinib.]
[J01DD12, cefoperazone, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefoperazone.]
[J01DD01, cefotaxime, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefotaxime.]
[J01DC05, cefotetan, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefotetan.]
[J01DC07, cefotiam, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefotiam.]
[J01DC01, cefoxitin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefoxitin.]
[J01DD03, cefsulodin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefsulodin.]
[J01DD02, ceftazidime, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Ceftazidime.]
[C03BX03, cicletanine, The therapeutic efficacy of Cicletanine can be decreased when used in combination with Mesalazine.]
[J01DD07, ceftizoxime, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Ceftizoxime.]
[J01DD04, ceftriaxone, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Ceftriaxone.]
[S01AA27, cefuroxime, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefuroxime.]
[L01EJ02, fedratinib, The excretion of Mesalazine can be decreased when combined with Fedratinib.]
[N07XX11, pitolisant, The risk or severity of adverse effects can be increased when Mesalazine is combined with Pitolisant.]
[N04CX01, istradefylline, The excretion of Mesalazine can be decreased when combined with Istradefylline.]
[A06AX08, tenapanor, The serum concentration of Mesalazine can be decreased when it is combined with Tenapanor.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Cyclothiazide can be decreased when used in combination with Mesalazine.]
[G04BE04, yohimbine, The risk or severity of hypertension can be increased when Mesalazine is combined with Yohimbine.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Mesalazine is combined with Insulin pork.]
[J01XX09, daptomycin, Mesalazine may decrease the excretion rate of Daptomycin which could result in a higher serum level.]
[J01DB01, cephalexin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cephalexin.]
[J01DB02, cephaloridine, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefaloridine.]
[J01DB03, cephalothin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefalotin.]
[J01DB08, cephapirin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefapirin.]
[J01DB09, cephradine, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefradine.]
[H02AB13, deflazacort, The risk or severity of gastrointestinal irritation can be increased when Deflazacort is combined with Mesalazine.]
[A16AX16, givosiran, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Givosiran.]
[M09AX08, golodirsen, Mesalazine may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[S01XA12, dexpanthenol, Mesalazine may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[C10AX15, bempedoic acid, The excretion of Mesalazine can be decreased when combined with Bempedoic acid.]
[J05AB16, remdesivir, The excretion of Mesalazine can be decreased when combined with Remdesivir.]
[S01AE06, gatifloxacin, Mesalazine may increase the neuroexcitatory activities of Gatifloxacin.]
[J05AE05, amprenavir, The excretion of Mesalazine can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of hypertension can be increased when Mesalazine is combined with Frovatriptan.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Mesalazine is combined with Dutasteride.]
[R02AA03, dichlorobenzyl alcohol, Mesalazine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Mesalazine may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[N02CC06, eletriptan, The risk or severity of hypertension can be increased when Eletriptan is combined with Mesalazine.]
[M01AH02, rofecoxib, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Rofecoxib.]
[C08CA16, clevidipine, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Clevidipine.]
[C01BD07, dronedarone, The risk or severity of hypertension can be increased when Mesalazine is combined with Dronedarone.]
[C02AA06, methoserpidine, The therapeutic efficacy of Methoserpidine can be decreased when used in combination with Mesalazine.]
[C01CA14, dopexamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Dopexamine.]
[D07XB03, fluprednidene, The risk or severity of gastrointestinal irritation can be increased when Fluprednidene is combined with Mesalazine.]
[M01AC04, droxicam, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Droxicam.]
[V08CA05, mangafodipir, Mesalazine may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, The risk or severity of hypertension can be increased when Mesalazine is combined with Selpercatinib.]
[B01AE02, lepirudin, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Lepirudin.]
[M02AA27, dexketoprofen, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Dexketoprofen.]
[C08CA17, levamlodipine, The therapeutic efficacy of Levamlodipine can be decreased when used in combination with Mesalazine.]
[J05AX29, fostemsavir, The excretion of Mesalazine can be decreased when combined with Fostemsavir.]
[P01BA01, chloroquine, Mesalazine may decrease the excretion rate of Chloroquine which could result in a higher serum level.]
[L01EX23, pralsetinib, The excretion of Mesalazine can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mesalazine.]
[N05AA01, chlorpromazine, The risk or severity of hypertension can be increased when Mesalazine is combined with Chlorpromazine.]
[A10BB02, chlorpropamide, Mesalazine may increase the hypoglycemic activities of Chlorpropamide.]
[C03BA04, chlorthalidone, The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Mesalazine.]
[M03BB03, chlorzoxazone, Mesalazine may decrease the excretion rate of Chlorzoxazone which could result in a higher serum level.]
[V04CK02, cholecystokinin, The excretion of Mesalazine can be decreased when combined with Cholecystokinin.]
[N02BA07, ethenzamide, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Ethenzamide.]
[C10AC01, cholestyramine resin, Cholestyramine can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N02BA03, choline salicylate, The therapeutic efficacy of Choline salicylate can be decreased when used in combination with Mesalazine.]
[N06BX18, vinpocetine, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Vinpocetine.]
[M01AB08, etodolac, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Etodolac.]
[M02AA06, etofenamate, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Etofenamate.]
[M01AX25, chondroitin sulfates, Mesalazine may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Mesalazine is combined with Naxitamab.]
[M01AE05, fenbufen, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Fenbufen.]
[C01CA19, fenoldopam, The therapeutic efficacy of Fenoldopam can be decreased when used in combination with Mesalazine.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Mesalazine is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Mesalazine is combined with Finasteride.]
[J01DD15, cefdinir, Mesalazine may decrease the excretion rate of Cefdinir which could result in a higher serum level.]
[J01MB07, flumequine, Mesalazine may increase the neuroexcitatory activities of Flumequine.]
[R03BA03, flunisolide, The risk or severity of gastrointestinal irritation can be increased when Flunisolide is combined with Mesalazine.]
[S02BA08, fluocinolone acetonide, The risk or severity of gastrointestinal irritation can be increased when Fluocinolone acetonide is combined with Mesalazine.]
[N02BG07, flupirtine, Mesalazine may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The risk or severity of hypertension can be increased when Mesalazine is combined with Formoterol.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Mesalazine is combined with Insulin human.]
[N01AB05, trichloroethylene, The risk or severity of hypertension can be increased when Mesalazine is combined with Trichloroethylene.]
[H04AA02, dasiglucagon, The therapeutic efficacy of Dasiglucagon can be decreased when used in combination with Mesalazine.]
[A02BA01, cimetidine, Cimetidine can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V08CA04, gadoteridol, Mesalazine may decrease the excretion rate of Gadoteridol which could result in a higher serum level.]
[N07CA02, cinnarizine, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Cinnarizine.]
[J01MB06, cinoxacin, Mesalazine may increase the neuroexcitatory activities of Cinoxacin.]
[S03AA07, ciprofloxacin, Mesalazine may increase the neuroexcitatory activities of Ciprofloxacin.]
[L01XA01, cisplatin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cisplatin.]
[N06AB04, citalopram, The risk or severity of gastrointestinal bleeding can be increased when Citalopram is combined with Mesalazine.]
[C03DA05, finerenone, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Finerenone.]
[L04AA48, belumosudil, The excretion of Mesalazine can be decreased when combined with Belumosudil.]
[V09AB03, ioflupane I-123, Mesalazine may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Mesalazine may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Mesalazine may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[A10BB12, glimepiride, Mesalazine may increase the hypoglycemic activities of Glimepiride.]
[A10BB08, gliquidone, Mesalazine may increase the hypoglycemic activities of Gliquidone.]
[R03CC13, clenbuterol, The risk or severity of hypertension can be increased when Mesalazine is combined with Clenbuterol.]
[B01AD11, tenecteplase, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Tenecteplase.]
[N01BB10, levobupivacaine, Mesalazine may decrease the excretion rate of Levobupivacaine which could result in a higher serum level.]
[N06AA04, clomipramine, The risk or severity of gastrointestinal bleeding can be increased when Clomipramine is combined with Mesalazine.]
[N03AE01, clonazepam, Mesalazine may decrease the excretion rate of Clonazepam which could result in a higher serum level.]
[S01EA04, clonidine, The therapeutic efficacy of Clonidine can be decreased when used in combination with Mesalazine.]
[J05AH02, oseltamivir, Mesalazine may decrease the excretion rate of Oseltamivir which could result in a higher serum level.]
[A10BX16, tirzepatide, Mesalazine may increase the hypoglycemic activities of Tirzepatide.]
[A02BC08, vonoprazan, Vonoprazan can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M02AA08, felbinac, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Felbinac.]
[N05AH02, clozapine, The risk or severity of hypertension can be increased when Mesalazine is combined with Clozapine.]
[A10BX01, guar gum, Mesalazine may increase the hypoglycemic activities of Guar gum.]
[A10BK06, sotagliflozin, Mesalazine may increase the hypoglycemic activities of Sotagliflozin.]
[J01GB12, arbekacin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Arbekacin.]
[C02KB01, metyrosine, The therapeutic efficacy of Metyrosine can be decreased when used in combination with Mesalazine.]
[M01AX13, proquazone, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Proquazone.]
[M04AC01, colchicine, Mesalazine may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[C10AC02, colestipol, Colestipol can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01XB01, colistin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Colistin.]
[L01XX40, omacetaxine mepesuccinate, The risk or severity of bleeding can be increased when Mesalazine is combined with Omacetaxine mepesuccinate.]
[J01DE02, cefpirome, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefpirome.]
[A02AD04, hydrotalcite, Hydrotalcite can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N01AB07, desflurane, The risk or severity of hypertension can be increased when Mesalazine is combined with Desflurane.]
[A04AA03, tropisetron, Mesalazine may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[C04AX28, ifenprodil, The risk or severity of hypertension can be increased when Mesalazine is combined with Ifenprodil.]
[A10BX03, nateglinide, Mesalazine may increase the hypoglycemic activities of Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Imidazole salicylate.]
[H01AC03, mecasermin, Mesalazine may increase the hypoglycemic activities of Mecasermin.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Mesalazine is combined with Insulin glargine.]
[J01FA15, telithromycin, The excretion of Mesalazine can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of gastrointestinal irritation can be increased when Ciclesonide is combined with Mesalazine.]
[B01AC10, indobufen, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Indobufen.]
[J05AB14, valganciclovir, Mesalazine may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Mesalazine may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Mesalazine may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Mesalazine may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Mesalazine may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Mesalazine may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Valdecoxib.]
[C01AA06, lanatoside C, The serum concentration of Lanatoside C can be decreased when it is combined with Mesalazine.]
[A03AX10, isometheptene, The risk or severity of hypertension can be increased when Mesalazine is combined with Isometheptene.]
[N02CC05, almotriptan, The risk or severity of hypertension can be increased when Mesalazine is combined with Almotriptan.]
[M01AH04, parecoxib, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Parecoxib.]
[J02AC02, itraconazole, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Bemiparin.]
[S01AD03, acyclovir, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Acyclovir.]
[N05BA10, ketazolam, Mesalazine may decrease the excretion rate of Ketazolam which could result in a higher serum level.]
[M01AA06, kebuzone, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Kebuzone.]
[A02BC05, esomeprazole, Esomeprazole can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01EE04, travoprost, The therapeutic efficacy of Travoprost can be decreased when used in combination with Mesalazine.]
[S01EE03, bimatoprost, The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Mesalazine.]
[C08CA09, lacidipine, The therapeutic efficacy of Lacidipine can be decreased when used in combination with Mesalazine.]
[N03AX09, lamotrigine, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Lamotrigine.]
[S01BA03, cortisone, The risk or severity of gastrointestinal irritation can be increased when Cortisone is combined with Mesalazine.]
[N07BC04, lofexidine, The therapeutic efficacy of Lofexidine can be decreased when used in combination with Mesalazine.]
[S01AE04, lomefloxacin, Mesalazine may increase the neuroexcitatory activities of Lomefloxacin.]
[M01AB09, lonazolac, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Lonazolac.]
[M02AA31, loxoprofen, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Loxoprofen.]
[J01DC08, loracarbef, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Loracarbef.]
[C09AA03, lisinopril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Lisinopril.]
[A02AD02, magaldrate, Magaldrate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A06AD01, magnesium carbonate, Magnesium carbonate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C08CA11, manidipine, The therapeutic efficacy of Manidipine can be decreased when used in combination with Mesalazine.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Mesalazine is combined with Mefenorex.]
[C07AA14, mepindolol, Mesalazine may decrease the antihypertensive activities of Mepindolol.]
[H02AB15, meprednisone, The risk or severity of gastrointestinal irritation can be increased when Meprednisone is combined with Mesalazine.]
[J01DH02, meropenem, Mesalazine may decrease the excretion rate of Meropenem which could result in a higher serum level.]
[C04AX01, cyclandelate, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Cyclandelate.]
[R03CB02, methoxyphenamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Methoxyphenamine.]
[S01BC10, nepafenac, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Nepafenac.]
[C03DA04, eplerenone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Eplerenone.]
[N05AD03, metylperon, Mesalazine may decrease the excretion rate of Melperone which could result in a higher serum level.]
[S01AA22, micronomicin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Micronomicin.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Mesalazine.]
[A10BF02, miglitol, Mesalazine may increase the hypoglycemic activities of Miglitol.]
[J05AF07, tenofovir disoproxil, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Tenofovir disoproxil.]
[N06AX07, minaprine, The risk or severity of hypertension can be increased when Mesalazine is combined with Minaprine.]
[S01XA18, cyclosporine, The risk or severity of renal failure and hypertension can be increased when Mesalazine is combined with Cyclosporine.]
[N06AG02, moclobemide, The risk or severity of hypertension can be increased when Mesalazine is combined with Moclobemide.]
[C09AA13, moexipril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Moexipril.]
[C10AA07, rosuvastatin, The excretion of Mesalazine can be decreased when combined with Rosuvastatin.]
[M02AA02, mofebutazone, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Morniflumate.]
[C02AC05, moxonidine, The therapeutic efficacy of Moxonidine can be decreased when used in combination with Mesalazine.]
[M01AH05, etoricoxib, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Etoricoxib.]
[L01AX04, dacarbazine, Mesalazine may decrease the excretion rate of Dacarbazine which could result in a higher serum level.]
[M03CA01, dantrolene, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Dantrolene.]
[C02CC04, debrisoquin, The therapeutic efficacy of Debrisoquine can be decreased when used in combination with Mesalazine.]
[M01AX01, nabumetone, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Nabumetone.]
[N07BB05, nalmefene, Mesalazine may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[B05XA15, potassium lactate, Potassium lactate may increase the hyperkalemic activities of Mesalazine.]
[C07AB12, nebivolol, Mesalazine may decrease the antihypertensive activities of Nebivolol.]
[S01GX04, nedocromil, Mesalazine may decrease the excretion rate of Nedocromil which could result in a higher serum level.]
[N06AX06, nefazodone, The risk or severity of gastrointestinal bleeding can be increased when Nefazodone is combined with Mesalazine.]
[C01DX16, nicorandil, The therapeutic efficacy of Nicorandil can be decreased when used in combination with Mesalazine.]
[L02BB02, nilutamide, Mesalazine may decrease the excretion rate of Nilutamide which could result in a higher serum level.]
[C01CA23, theodrenaline, The risk or severity of hypertension can be increased when Mesalazine is combined with Theodrenaline.]
[C01CA05, norfenefrine, The risk or severity of hypertension can be increased when Mesalazine is combined with Norfenefrine.]
[B01AX05, fondaparinux, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Fondaparinux.]
[N06AB10, escitalopram, The risk or severity of gastrointestinal bleeding can be increased when Escitalopram is combined with Mesalazine.]
[G04BD08, solifenacin, The risk or severity of hypertension can be increased when Mesalazine is combined with Solifenacin.]
[A07EC03, olsalazine, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Olsalazine.]
[N06AA01, desipramine, The risk or severity of gastrointestinal bleeding can be increased when Desipramine is combined with Mesalazine.]
[C01AA07, deslanoside, The serum concentration of Deslanoside can be decreased when it is combined with Mesalazine.]
[H01BA02, desmopressin, The risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Mesalazine is combined with Desmopressin.]
[D07XC02, desoximetasone, The risk or severity of gastrointestinal irritation can be increased when Desoximetasone is combined with Mesalazine.]
[V04CH02, indigo carmine, Mesalazine may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[H02AA03, desoxycorticosterone, The risk or severity of gastrointestinal irritation can be increased when Desoxycortone is combined with Mesalazine.]
[J01DH03, ertapenem, Mesalazine may decrease the excretion rate of Ertapenem which could result in a higher serum level.]
[C09XA02, aliskiren, The risk or severity of renal failure and hypertension can be increased when Mesalazine is combined with Aliskiren.]
[M01AE12, oxaprozin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Oxaprozin.]
[S03BA01, dexamethasone, The risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Mesalazine.]
[N06BA02, dextroamphetamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Mesalazine.]
[N06AB05, paroxetine, The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Mesalazine.]
[B01AC04, clopidogrel, The risk or severity of bleeding can be increased when Mesalazine is combined with Clopidogrel.]
[P03AC04, permethrin, Mesalazine may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, Mesalazine may decrease the excretion rate of Diazepam which could result in a higher serum level.]
[V03AH01, diazoxide, The therapeutic efficacy of Diazoxide can be decreased when used in combination with Mesalazine.]
[S01AA29, dibekacin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Dibekacin.]
[N06AA08, dibenzepin, The risk or severity of gastrointestinal bleeding can be increased when Dibenzepin is combined with Mesalazine.]
[R05DA08, pholcodine, Mesalazine may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[M05BA02, clodronic acid, The risk or severity of gastrointestinal bleeding can be increased when Mesalazine is combined with Clodronic acid.]
[S01EC02, dichlorphenamide, The risk or severity of adverse effects can be increased when Mesalazine is combined with Diclofenamide.]
[S01BC03, diclofenac, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Diclofenac.]
[J05AD01, foscarnet, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Foscarnet.]
[A03AA07, dicyclomine, Mesalazine may decrease the excretion rate of Dicyclomine which could result in a higher serum level.]
[J05AF02, didanosine, Mesalazine may decrease the excretion rate of Didanosine which could result in a higher serum level.]
[C02DG01, pinacidil, The therapeutic efficacy of Pinacidil can be decreased when used in combination with Mesalazine.]
[A03AX04, pinaverium, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Pinaverium.]
[A10BG03, pioglitazone, Mesalazine may increase the hypoglycemic activities of Pioglitazone.]
[R03CC07, pirbuterol, The risk or severity of hypertension can be increased when Mesalazine is combined with Pirbuterol.]
[C03CA03, piretanide, The therapeutic efficacy of Piretanide can be decreased when used in combination with Mesalazine.]
[A08AA03, diethylpropion, The risk or severity of hypertension can be increased when Mesalazine is combined with Diethylpropion.]
[L02AA01, diethylstilbestrol, The excretion of Mesalazine can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The therapeutic efficacy of Isradipine can be decreased when used in combination with Mesalazine.]
[D07XC04, diflucortolone, The risk or severity of gastrointestinal irritation can be increased when Difluocortolone is combined with Mesalazine.]
[N02BA11, diflunisal, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Diflunisal.]
[C01AA04, digitoxin, The serum concentration of Digitoxin can be decreased when it is combined with Mesalazine.]
[C01AA05, digoxin, Mesalazine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02DB01, dihydralazine, The therapeutic efficacy of Dihydralazine can be decreased when used in combination with Mesalazine.]
[C04AE04, dihydroergocristine, The risk or severity of hypertension can be increased when Mesalazine is combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Dihydroergotamine.]
[N02AA03, hydromorphone, Mesalazine may decrease the excretion rate of Hydromorphone which could result in a higher serum level.]
[L04AX04, lenalidomide, Mesalazine may decrease the excretion rate of Lenalidomide which could result in a higher serum level.]
[J05AE08, atazanavir, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of bleeding can be increased when Treprostinil is combined with Mesalazine.]
[H03BC01, potassium perchlorate, Potassium perchlorate may increase the hyperkalemic activities of Mesalazine.]
[V03AB04, pralidoxime, Mesalazine may decrease the excretion rate of Pralidoxime which could result in a higher serum level.]
[C08DB01, diltiazem, The risk or severity of bleeding can be increased when Diltiazem is combined with Mesalazine.]
[V03AB09, dimercaprol, Mesalazine may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[R03CC08, procaterol, The risk or severity of hypertension can be increased when Mesalazine is combined with Procaterol.]
[M02AX03, dimethyl sulfoxide, Mesalazine may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N02BB04, propyphenazone, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Proglumetacin.]
[G02AD01, dinoprost, The therapeutic efficacy of Dinoprost can be decreased when used in combination with Mesalazine.]
[C09AA06, quinapril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Quinapril.]
[B01AC07, dipyridamole, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Dipyridamole.]
[N06BA11, dexmethylphenidate, The risk or severity of hypertension can be increased when Mesalazine is combined with Dexmethylphenidate.]
[B01AD10, drotrecogin alfa, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Drotrecogin alfa.]
[N06AA23, quinupramine, The risk or severity of gastrointestinal bleeding can be increased when Quinupramine is combined with Mesalazine.]
[C09AA05, ramipril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Ramipril.]
[S01XA23, sirolimus, The excretion of Mesalazine can be decreased when combined with Sirolimus.]
[R03CC14, reproterol, The risk or severity of hypertension can be increased when Mesalazine is combined with Reproterol.]
[S01AX06, resorcinol, Mesalazine may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Mesalazine may increase the hypoglycemic activities of Disopyramide.]
[S02AA12, rifamycin SV, The excretion of Mesalazine can be decreased when combined with Rifamycin.]
[N05AX08, risperidone, The risk or severity of hypertension can be increased when Mesalazine is combined with Risperidone.]
[R06AE09, levocetirizine, Mesalazine may decrease the excretion rate of Levocetirizine which could result in a higher serum level.]
[N01BB09, ropivacaine, Mesalazine may decrease the excretion rate of Ropivacaine which could result in a higher serum level.]
[J01MB01, rosoxacin, Mesalazine may increase the neuroexcitatory activities of Rosoxacin.]
[L01EX01, sunitinib, Mesalazine may increase the hypoglycemic activities of Sunitinib.]
[C03XA01, tolvaptan, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Tolvaptan.]
[G04BE08, tadalafil, The therapeutic efficacy of Tadalafil can be decreased when used in combination with Mesalazine.]
[S01BC05, ketorolac, The risk or severity of adverse effects can be increased when Ketorolac is combined with Mesalazine.]
[C02KX02, ambrisentan, The therapeutic efficacy of Ambrisentan can be decreased when used in combination with Mesalazine.]
[C01EB18, ranolazine, Mesalazine may decrease the excretion rate of Ranolazine which could result in a higher serum level.]
[N02BA06, salsalate, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of hypertension can be increased when Mesalazine is combined with Salmeterol.]
[H05BA01, salmon calcitonin, Mesalazine may decrease the excretion rate of Salmon calcitonin which could result in a higher serum level.]
[C01CA07, dobutamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Dobutamine.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Dopamine.]
[N06AA16, dothiepin, The risk or severity of gastrointestinal bleeding can be increased when Dosulepin is combined with Mesalazine.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Mesalazine is combined with Doxapram.]
[N06AA12, doxepin, The therapeutic efficacy of Mesalazine can be decreased when used in combination with Doxepin.]
[J01AA02, doxycycline, Mesalazine may decrease the excretion rate of Doxycycline which could result in a higher serum level.]
[N06AB06, sertraline, The risk or severity of bleeding can be increased when Mesalazine is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of hypertension can be increased when Mesalazine is combined with Sevoflurane.]
[N05AD08, droperidol, The risk or severity of hypertension can be increased when Mesalazine is combined with Droperidol.]
[A08AA10, sibutramine, The risk or severity of gastrointestinal bleeding can be increased when Sibutramine is combined with Mesalazine.]
[C10AA01, simvastatin, The excretion of Mesalazine can be decreased when combined with Simvastatin.]
[B05XA02, sodium bicarbonate, Sodium bicarbonate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AG05, sodium phosphate, The risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Mesalazine.]
[A12CA02, sodium sulfate, Mesalazine may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[C09AA11, spirapril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Spirapril.]
[R03DA01, dyphylline, Mesalazine may decrease the excretion rate of Dyphylline which could result in a higher serum level.]
[N02CC01, sumatriptan, The risk or severity of hypertension can be increased when Mesalazine is combined with Sumatriptan.]
[V04CX07, edrophonium, Mesalazine may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[C07AB13, talinolol, Mesalazine may decrease the antihypertensive activities of Talinolol.]
[H01AA01, corticotropin, The risk or severity of gastrointestinal irritation can be increased when Corticotropin is combined with Mesalazine.]
[J01MA05, temafloxacin, Mesalazine may increase the neuroexcitatory activities of Temafloxacin.]
[L01AX03, temozolomide, Mesalazine may decrease the excretion rate of Temozolomide which could result in a higher serum level.]
[M01AC02, tenoxicam, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Tenoxicam.]
[G04CA03, terazosin, The therapeutic efficacy of Terazosin can be decreased when used in combination with Mesalazine.]
[G04BD05, terodiline, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Terodiline.]
[C07AA16, tertatolol, Mesalazine may decrease the antihypertensive activities of Tertatolol.]
[S01GA02, tetrahydrozoline, The risk or severity of hypertension can be increased when Mesalazine is combined with Tetryzoline.]
[N06AX14, tianeptine, The risk or severity of gastrointestinal bleeding can be increased when Tianeptine is combined with Mesalazine.]
[C09AA02, enalapril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Enalapril.]
[M01AG02, tolfenamic acid, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Tolfenamic acid.]
[N06AG03, toloxatone, The risk or severity of hypertension can be increased when Mesalazine is combined with Toloxatone.]
[N06BA09, atomoxetine, The risk or severity of hypertension can be increased when Mesalazine is combined with Atomoxetine.]
[N03AX11, topiramate, Mesalazine may decrease the excretion rate of Topiramate which could result in a higher serum level.]
[C03CA04, torsemide, The therapeutic efficacy of Torasemide can be decreased when used in combination with Mesalazine.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Mesalazine is combined with Tramazoline.]
[C09AA10, trandolapril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Trandolapril.]
[N05CC01, chloral hydrate, Mesalazine may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[B01AC18, triflusal, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Triflusal.]
[H02CA01, trilostane, The risk or severity of gastrointestinal irritation can be increased when Trilostane is combined with Mesalazine.]
[C05CA04, troxerutin, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Troxerutin.]
[R03CC11, tulobuterol, The risk or severity of hypertension can be increased when Mesalazine is combined with Tulobuterol.]
[C02CA06, urapidil, The therapeutic efficacy of Urapidil can be decreased when used in combination with Mesalazine.]
[J01MA04, enoxacin, Mesalazine may increase the neuroexcitatory activities of Enoxacin.]
[S01FB02, ephedrine, The risk or severity of hypertension can be increased when Mesalazine is combined with Ephedrine.]
[S01GX10, epinastine, The therapeutic efficacy of Mesalazine can be decreased when used in combination with Epinastine.]
[N06AX16, venlafaxine, Venlafaxine may increase the antiplatelet activities of Mesalazine.]
[C01CX07, xamoterol, The risk or severity of hypertension can be increased when Mesalazine is combined with Xamoterol.]
[S01GA03, xylometazoline, The risk or severity of hypertension can be increased when Mesalazine is combined with Xylometazoline.]
[C08CA12, mepirodipine, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Barnidipine.]
[S01EA01, epinephrine, The risk or severity of hypertension can be increased when Mesalazine is combined with Epinephrine.]
[C09AA15, zofenopril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Zofenopril.]
[M01AB04, zomepirac, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Mesalazine is combined with Zonisamide.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Mesalazine is combined with Insulin glulisine.]
[B01AD03, anistreplase, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Anistreplase.]
[L01XA02, carboplatin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Carboplatin.]
[C02AC02, guanfacine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Mesalazine.]
[B01AC11, iloprost, The risk or severity of bleeding can be increased when Mesalazine is combined with Iloprost.]
[G02AB03, ergonovine, The risk or severity of hypertension can be increased when Mesalazine is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of hypertension can be increased when Mesalazine is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Ergotamine.]
[N03AG01, valproic acid, The serum concentration of Valproic acid can be increased when it is combined with Mesalazine.]
[L03AX05, pidotimod, Mesalazine may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The excretion of Mesalazine can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, Mesalazine may decrease the excretion rate of Estazolam which could result in a higher serum level.]
[A02BC02, pantoprazole, Pantoprazole can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G03CA03, estradiol, The excretion of Mesalazine can be decreased when combined with Estradiol.]
[G03CA57, estrogens, conjugated (USP), The excretion of Mesalazine can be decreased when combined with Conjugated estrogens.]
[J04AK02, ethambutol, Mesalazine may decrease the excretion rate of Ethambutol which could result in a higher serum level.]
[R03BA05, fluticasone, The risk or severity of gastrointestinal irritation can be increased when Fluticasone is combined with Mesalazine.]
[C10AA04, fluvastatin, The excretion of Mesalazine can be decreased when combined with Fluvastatin.]
[V08CA03, gadodiamide, Mesalazine may decrease the excretion rate of Gadodiamide which could result in a higher serum level.]
[C01CA15, gepefrine, The risk or severity of hypertension can be increased when Mesalazine is combined with Gepefrine.]
[C01BD05, ibutilide, Mesalazine may decrease the excretion rate of Ibutilide which could result in a higher serum level.]
[N03AD01, ethosuximide, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Ethosuximide.]
[M01AC06, meloxicam, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Meloxicam.]
[C01CA01, etilefrine, The risk or severity of hypertension can be increased when Mesalazine is combined with Etilefrine.]
[N01AX07, etomidate, The risk or severity of hypertension can be increased when Mesalazine is combined with Etomidate.]
[L04AD02, tacrolimus, The risk or severity of renal failure can be increased when Mesalazine is combined with Tacrolimus.]
[A02BA04, nizatidine, Nizatidine can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01MA08, fleroxacin, Mesalazine may increase the neuroexcitatory activities of Fleroxacin.]
[P01AX07, trimetrexate, Mesalazine may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, Mesalazine may decrease the excretion rate of Bupropion which could result in a higher serum level.]
[N06AB08, fluvoxamine, The risk or severity of gastrointestinal bleeding can be increased when Fluvoxamine is combined with Mesalazine.]
[L02AE02, leuprolide, Mesalazine may decrease the excretion rate of Leuprolide which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, Mesalazine may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Dextran.]
[M05BA01, etidronic acid, The risk or severity of gastrointestinal bleeding can be increased when Mesalazine is combined with Etidronic acid.]
[V03AF02, dexrazoxane, Mesalazine may decrease the excretion rate of Dexrazoxane which could result in a higher serum level.]
[A02BA03, famotidine, Famotidine can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A16AA01, levocarnitine, The excretion of Mesalazine can be decreased when combined with Levocarnitine.]
[C08CA02, felodipine, The therapeutic efficacy of Felodipine can be decreased when used in combination with Mesalazine.]
[C08EA01, fendiline, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Fendiline.]
[M01AE04, fenoprofen, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Fenoprofen.]
[R03CC04, fenoterol, The risk or severity of hypertension can be increased when Mesalazine is combined with Fenoterol.]
[N02AB03, fentanyl, The risk or severity of hypertension can be increased when Mesalazine is combined with Fentanyl.]
[R03CC02, albuterol, The risk or severity of hypertension can be increased when Mesalazine is combined with Salbutamol.]
[S01EE01, latanoprost, The therapeutic efficacy of Latanoprost can be decreased when used in combination with Mesalazine.]
[B01AD05, plasmin, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Fibrinolysin.]
[L01BB06, clofarabine, Mesalazine may decrease the excretion rate of Clofarabine which could result in a higher serum level.]
[N07AX03, cevimeline, Mesalazine may decrease the excretion rate of Cevimeline which could result in a higher serum level.]
[G04BD02, flavoxate, Mesalazine may decrease the excretion rate of Flavoxate which could result in a higher serum level.]
[N02BG04, floctafenine, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Floctafenine.]
[J02AC01, fluconazole, The risk or severity of hyperkalemia can be increased when Fluconazole is combined with Mesalazine.]
[J02AX01, flucytosine, Mesalazine may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[H02AA02, fludrocortisone, The risk or severity of gastrointestinal irritation can be increased when Fludrocortisone is combined with Mesalazine.]
[V03AB25, flumazenil, Mesalazine may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[D07XB01, flumethasone, The risk or severity of gastrointestinal irritation can be increased when Flumethasone is combined with Mesalazine.]
[N07CA03, flunarizine, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Flunarizine.]
[D07AC08, fluocinonide, The risk or severity of gastrointestinal irritation can be increased when Fluocinonide is combined with Mesalazine.]
[N06AA14, melitracen, The risk or severity of gastrointestinal bleeding can be increased when Melitracen is combined with Mesalazine.]
[H02AB03, fluocortolone, The risk or severity of gastrointestinal irritation can be increased when Fluocortolone is combined with Mesalazine.]
[V03AZ01, ethanol, The risk or severity of gastrointestinal irritation can be increased when Ethanol is combined with Mesalazine.]
[L01BC09, floxuridine, Mesalazine may decrease the excretion rate of Floxuridine which could result in a higher serum level.]
[S01CB05, fluorometholone, The risk or severity of gastrointestinal irritation can be increased when Fluorometholone is combined with Mesalazine.]
[N06AB03, fluoxetine, The risk or severity of gastrointestinal bleeding can be increased when Fluoxetine is combined with Mesalazine.]
[N05AF01, flupenthixol, The risk or severity of hypertension can be increased when Mesalazine is combined with Flupentixol.]
[N05CD01, flurazepam, Mesalazine may decrease the excretion rate of Flurazepam which could result in a higher serum level.]
[S01BC04, flurbiprofen, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Fluspirilene.]
[L02BB01, flutamide, Mesalazine may decrease the excretion rate of Flutamide which could result in a higher serum level.]
[V04CX02, folic acid, Mesalazine may decrease the excretion rate of Folic acid which could result in a higher serum level.]
[S02AA17, fosfomycin, Mesalazine may decrease the excretion rate of Fosfomycin which could result in a higher serum level.]
[S01AA07, framycetin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Framycetin.]
[L01BC03, tegafur, Mesalazine may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[N06BX17, adrafinil, The risk or severity of hypertension can be increased when Mesalazine is combined with Adrafinil.]
[G01AX06, furazolidone, The risk or severity of hypertension can be increased when Mesalazine is combined with Furazolidone.]
[J05AE10, darunavir, The excretion of Mesalazine can be decreased when combined with Darunavir.]
[C03CA01, furosemide, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Furosemide.]
[M05BA04, alendronic acid, The risk or severity of adverse effects can be increased when Mesalazine is combined with Alendronic acid.]
[N05CF04, eszopiclone, Mesalazine may decrease the excretion rate of Eszopiclone which could result in a higher serum level.]
[C08DA02, gallopamil, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Gallopamil.]
[S01AD09, ganciclovir, Mesalazine may decrease the excretion rate of Ganciclovir which could result in a higher serum level.]
[C10AB04, gemfibrozil, The excretion of Mesalazine can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, Mesalazine may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[N04BC06, cabergoline, The risk or severity of hypertension can be increased when Mesalazine is combined with Cabergoline.]
[A10BJ02, liraglutide, Mesalazine may increase the hypoglycemic activities of Liraglutide.]
[N03AD03, methsuximide, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of hypertension can be increased when Mesalazine is combined with Alfentanil.]
[A10BB01, glyburide, Mesalazine may increase the hypoglycemic activities of Glyburide.]
[A10BB09, gliclazide, Mesalazine may increase the hypoglycemic activities of Gliclazide.]
[A10BB07, glipizide, Mesalazine may increase the hypoglycemic activities of Glipizide.]
[N05CM18, dexmedetomidine, The risk or severity of hypertension can be increased when Mesalazine is combined with Dexmedetomidine.]
[C05AE01, nitroglycerin, The therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Mesalazine.]
[C02CA04, doxazosin, The therapeutic efficacy of Doxazosin can be decreased when used in combination with Mesalazine.]
[H01AB01, thyrotropin alfa, The therapeutic efficacy of Thyrotropin alfa can be increased when used in combination with Mesalazine.]
[L01EX02, sorafenib, The excretion of Mesalazine can be decreased when combined with Sorafenib.]
[C07AB09, esmolol, Mesalazine may decrease the antihypertensive activities of Esmolol.]
[M01CB04, aurothioglucose, Mesalazine may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Mesalazine may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Fluindione.]
[C09AA09, fosinopril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Fosinopril.]
[S01EX01, guanethidine, The therapeutic efficacy of Guanethidine can be decreased when used in combination with Mesalazine.]
[L02AE03, goserelin, Mesalazine may decrease the excretion rate of Goserelin which could result in a higher serum level.]
[N05AD01, haloperidol, The therapeutic efficacy of Haloperidol can be increased when used in combination with Mesalazine.]
[N01AB01, halothane, The risk or severity of hypertension can be increased when Mesalazine is combined with Halothane.]
[N05AH04, quetiapine, The risk or severity of hypertension can be increased when Mesalazine is combined with Quetiapine.]
[N06BX13, idebenone, Mesalazine may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Mesalazine is combined with Insulin aspart.]
[L01CE02, irinotecan, The excretion of Mesalazine can be decreased when combined with Irinotecan.]
[M04AA01, allopurinol, Mesalazine may decrease the excretion rate of Allopurinol which could result in a higher serum level.]
[C09CA01, losartan, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Mesalazine.]
[S01XA14, heparin, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Heparin.]
[G03DC01, allylestrenol, Mesalazine may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[J01MB04, pipemidic acid, Mesalazine may increase the neuroexcitatory activities of Pipemidic acid.]
[M01AG01, mefenamic acid, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Mefenamic acid.]
[C01DA05, pentaerythritol tetranitrate, Mesalazine may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The risk or severity of gastrointestinal irritation can be increased when Fluticasone furoate is combined with Mesalazine.]
[C01CE02, milrinone, Mesalazine may decrease the excretion rate of Milrinone which could result in a higher serum level.]
[R03CC05, hexoprenaline, The risk or severity of hypertension can be increased when Mesalazine is combined with Hexoprenaline.]
[C08CA10, nilvadipine, The therapeutic efficacy of Nilvadipine can be decreased when used in combination with Mesalazine.]
[M02AA26, nimesulide, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Nimesulide.]
[C09AA04, perindopril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Perindopril.]
[C02DB02, hydralazine, Mesalazine may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Hydrochlorothiazide.]
[S02BA01, hydrocortisone, The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Mesalazine.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Mesalazine.]
[B05XA17, potassium acetate, Potassium acetate may increase the hyperkalemic activities of Mesalazine.]
[S01XA07, aluminum potassium sulfate, Potassium alum may increase the hyperkalemic activities of Mesalazine.]
[A12BA02, potassium citrate, Potassium citrate may increase the hyperkalemic activities of Mesalazine.]
[V03AB33, hydroxocobalamin, Mesalazine may decrease the excretion rate of Hydroxocobalamin which could result in a higher serum level.]
[G04BD06, propiverine, The risk or severity of hypertension can be increased when Mesalazine is combined with Propiverine.]
[B05AA07, hetastarch, Mesalazine may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[C02AC06, rilmenidine, The therapeutic efficacy of Rilmenidine can be decreased when used in combination with Mesalazine.]
[M05BA07, risedronic acid, The risk or severity of gastrointestinal bleeding can be increased when Mesalazine is combined with Risedronic acid.]
[R02AX02, ibuprofen, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Ibuprofen.]
[B05XA08, sodium acetate, Mesalazine may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[B05CB02, sodium citrate, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Sodium citrate.]
[L01AA06, ifosfamide, Mesalazine may decrease the excretion rate of Ifosfamide which could result in a higher serum level.]
[N01AH03, sufentanil, The risk or severity of hypertension can be increased when Mesalazine is combined with Sufentanil.]
[N06AA02, imipramine, The risk or severity of gastrointestinal bleeding can be increased when Imipramine is combined with Mesalazine.]
[R01AD07, tixocortol, The risk or severity of gastrointestinal irritation can be increased when Tixocortol is combined with Mesalazine.]
[L01CE01, topotecan, Mesalazine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03BA11, indapamide, The therapeutic efficacy of Indapamide can be decreased when used in combination with Mesalazine.]
[S01BC01, indomethacin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Indomethacin.]
[C02CA02, indoramin, The therapeutic efficacy of Indoramin can be decreased when used in combination with Mesalazine.]
[A11HA07, inositol, Mesalazine may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, The risk or severity of gastrointestinal bleeding can be increased when Milnacipran is combined with Mesalazine.]
[S01XA28, varenicline, Mesalazine may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[A10BH01, sitagliptin, Mesalazine may increase the hypoglycemic activities of Sitagliptin.]
[N05BA12, alprazolam, Mesalazine may decrease the excretion rate of Alprazolam which could result in a higher serum level.]
[N05CH02, ramelteon, Mesalazine may decrease the excretion rate of Ramelteon which could result in a higher serum level.]
[A10BH02, vildagliptin, Mesalazine may increase the hypoglycemic activities of Vildagliptin.]
[C10AA06, cerivastatin, The excretion of Mesalazine can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of bleeding can be increased when Mesalazine is combined with Anagrelide.]
[C07AA01, alprenolol, Mesalazine may decrease the antihypertensive activities of Alprenolol.]
[C03BA02, quinethazone, The therapeutic efficacy of Quinethazone can be decreased when used in combination with Mesalazine.]
[V03AB01, ipecac, Mesalazine may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AA13, iprindole, The risk or severity of gastrointestinal bleeding can be increased when Iprindole is combined with Mesalazine.]
[N06AF05, iproniazid, The risk or severity of hypertension can be increased when Mesalazine is combined with Iproniazid.]
[N06AF01, isocarboxazid, The risk or severity of hypertension can be increased when Mesalazine is combined with Isocarboxazid.]
[S01EC03, dorzolamide, The risk or severity of metabolic acidosis can be increased when Dorzolamide is combined with Mesalazine.]
[R03CC06, isoetharine, The risk or severity of hypertension can be increased when Isoetharine is combined with Mesalazine.]
[C09AA16, imidapril, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Imidapril.]
[N01AB06, isoflurane, The risk or severity of hypertension can be increased when Mesalazine is combined with Isoflurane.]
[J04AC01, isoniazid, Mesalazine may decrease the excretion rate of Isoniazid which could result in a higher serum level.]
[J05AX05, inosine pranobex, Mesalazine may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[R03CB01, isoproterenol, The risk or severity of hypertension can be increased when Mesalazine is combined with Isoprenaline.]
[A10BJ01, exenatide, Mesalazine may increase the hypoglycemic activities of Exenatide.]
[D10BA01, isotretinoin, Mesalazine may decrease the excretion rate of Isotretinoin which could result in a higher serum level.]
[C04AA01, isoxsuprine, The risk or severity of hypertension can be increased when Mesalazine is combined with Isoxsuprine.]
[P02CF01, ivermectin, The excretion of Mesalazine can be decreased when combined with Ivermectin.]
[B01AE06, bivalirudin, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Bivalirudin.]
[S01AA24, kanamycin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Kanamycin.]
[A02AB01, aluminum hydroxide, Aluminum hydroxide can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N01AX03, ketamine, Mesalazine may decrease the excretion rate of Ketamine which could result in a higher serum level.]
[C02KD01, ketanserin, The risk or severity of bleeding can be increased when Mesalazine is combined with Ketanserin.]
[B01AC22, prasugrel, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Prasugrel.]
[J02AB02, ketoconazole, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Ketoconazole.]
[N05AH03, olanzapine, The therapeutic efficacy of Mesalazine can be decreased when used in combination with Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Ketoprofen.]
[V03AC03, deferasirox, The risk or severity of gastrointestinal bleeding and peptic ulcer can be increased when Mesalazine is combined with Deferasirox.]
[C01CA22, arbutamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Arbutamine.]
[N04BC09, rotigotine, The risk or severity of hypertension can be increased when Mesalazine is combined with Rotigotine.]
[J01MB02, nalidixic acid, Mesalazine may increase the neuroexcitatory activities of Nalidixic acid.]
[C07AG01, labetalol, Mesalazine may decrease the antihypertensive activities of Labetalol.]
[N04BB01, amantadine, Mesalazine may decrease the excretion rate of Amantadine which could result in a higher serum level.]
[C02AA05, deserpidine, The therapeutic efficacy of Deserpidine can be decreased when used in combination with Mesalazine.]
[A06AD11, lactulose, Lactulose can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A06AX03, lubiprostone, Mesalazine may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[C08EX01, lidoflazine, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Lidoflazine.]
[S01AA21, amikacin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Amikacin.]
[C03DB01, amiloride, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Amiloride.]
[N02CA07, lisuride, The risk or severity of hypertension can be increased when Mesalazine is combined with Lisuride.]
[N06AA07, lofepramine, The risk or severity of gastrointestinal bleeding can be increased when Lofepramine is combined with Mesalazine.]
[A07DA03, loperamide, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Loperamide.]
[N05BA06, lorazepam, Mesalazine may decrease the excretion rate of Lorazepam which could result in a higher serum level.]
[C10AA02, lovastatin, The excretion of Mesalazine can be decreased when combined with Lovastatin.]
[B05XA11, magnesium chloride, Mesalazine may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Magnesium hydroxide can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC10, magnesium oxide, Magnesium oxide can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V04CC02, magnesium sulfate, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Magnesium sulfate.]
[L01BA05, pralatrexate, The serum concentration of Pralatrexate can be increased when it is combined with Mesalazine.]
[L01EA03, nilotinib, The excretion of Mesalazine can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Mannitol.]
[N06AA21, maprotiline, Mesalazine may decrease the excretion rate of Maprotiline which could result in a higher serum level.]
[C02BB01, mecamylamine, The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Mesalazine.]
[M02AA18, meclofenamic acid, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Meclofenamic acid.]
[C01AA08, medigoxin, Mesalazine may decrease the excretion rate of Metildigoxin which could result in a higher serum level.]
[B01AB06, nadroparin, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Dalteparin.]
[N06DX01, memantine, Mesalazine may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, Mesalazine may decrease the excretion rate of Meperidine which could result in a higher serum level.]
[C01CA11, mephentermine, The risk or severity of hypertension can be increased when Mesalazine is combined with Mephentermine.]
[N01BB03, mepivacaine, Mesalazine may decrease the excretion rate of Mepivacaine which could result in a higher serum level.]
[G04BX16, tiopronin, Mesalazine may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mesalazine may decrease the excretion rate of Mersalyl which could result in a higher serum level.]
[N05AX13, paliperidone, The risk or severity of hypertension can be increased when Mesalazine is combined with Paliperidone.]
[C01CA09, metaraminol, The risk or severity of hypertension can be increased when Mesalazine is combined with Metaraminol.]
[A10BA02, metformin, Mesalazine may increase the hypoglycemic activities of Metformin.]
[N07BC02, methadone, Mesalazine may decrease the excretion rate of Methadone which could result in a higher serum level.]
[N06BA03, methamphetamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Metamfetamine.]
[A03AB07, methantheline, Methantheline can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J05AF05, lamivudine, Mesalazine may decrease the excretion rate of Lamivudine which could result in a higher serum level.]
[S01EC05, methazolamide, The risk or severity of adverse effects can be increased when Mesalazine is combined with Methazolamide.]
[G02CB05, metergoline, The risk or severity of hypertension can be increased when Mesalazine is combined with Metergoline.]
[H03BB02, methimazole, Mesalazine may decrease the excretion rate of Methimazole which could result in a higher serum level.]
[L01BA04, pemetrexed, Mesalazine may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[A11HA02, pyridoxine, Mesalazine may decrease the excretion rate of Pyridoxine which could result in a higher serum level.]
[L04AX03, methotrexate, The serum concentration of Methotrexate can be increased when it is combined with Mesalazine.]
[N05AA02, methotrimeprazine, The risk or severity of hypertension can be increased when Mesalazine is combined with Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Methoxamine.]
[D05BA02, methoxsalen, Mesalazine may decrease the excretion rate of Methoxsalen which could result in a higher serum level.]
[N02BG09, methoxyflurane, The risk or severity of hypertension can be increased when Mesalazine is combined with Methoxyflurane.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mesalazine.]
[C02AB01, methyldopa, The therapeutic efficacy of Methyldopa can be decreased when used in combination with Mesalazine.]
[V04CG05, methylene blue, The risk or severity of hypertension can be increased when Mesalazine is combined with Methylene blue.]
[G02AB01, methylergonovine, The risk or severity of hypertension can be increased when Mesalazine is combined with Methylergometrine.]
[N06BA04, methylphenidate, The risk or severity of hypertension can be increased when Mesalazine is combined with Methylphenidate.]
[H02AB04, methylprednisolone, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Mesalazine.]
[D07AC14, methylprednisolone aceponate, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Mesalazine.]
[G03EK01, methyltestosterone, Mesalazine may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[N02CA04, methysergide, The risk or severity of hypertension can be increased when Mesalazine is combined with Methysergide.]
[A03FA01, metoclopramide, Mesalazine may decrease the excretion rate of Metoclopramide which could result in a higher serum level.]
[C03BA08, metolazone, The therapeutic efficacy of Metolazone can be decreased when used in combination with Mesalazine.]
[C07AB02, metoprolol, Mesalazine may decrease the antihypertensive activities of Metoprolol.]
[V04CD01, metyrapone, Mesalazine may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[N06AX03, mianserin, The risk or severity of hypertension can be increased when Mesalazine is combined with Mianserin.]
[N02BB03, aminopyrine, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Aminophenazone.]
[B01AB07, parnaparin, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Parnaparin.]
[N05CD08, midazolam, Mesalazine may decrease the excretion rate of Midazolam which could result in a higher serum level.]
[C01CA17, midodrine, The risk or severity of hypertension can be increased when Midodrine is combined with Mesalazine.]
[G03XB01, mifepristone, Mesalazine may increase the hypoglycemic activities of Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Tinzaparin.]
[J05AH01, zanamivir, Mesalazine may decrease the excretion rate of Zanamivir which could result in a higher serum level.]
[C09CA03, valsartan, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Valsartan is combined with Mesalazine.]
[D11AX01, minoxidil, The therapeutic efficacy of Minoxidil can be decreased when used in combination with Mesalazine.]
[N06BA12, lisdexamfetamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Lisdexamfetamine.]
[L03AC01, aldesleukin, Mesalazine may decrease the excretion rate of Aldesleukin which could result in a higher serum level.]
[C01BD01, amiodarone, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of gastrointestinal bleeding can be increased when Amitriptyline is combined with Mesalazine.]
[A04AA05, palonosetron, Mesalazine may decrease the excretion rate of Palonosetron which could result in a higher serum level.]
[J01DD06, moxalactam, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Latamoxef.]
[L04AB05, certolizumab pegol, Mesalazine may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.]
[B02BX05, eltrombopag, The excretion of Mesalazine can be decreased when combined with Eltrombopag.]
[G04BA01, ammonium chloride, The serum concentration of Mesalazine can be increased when it is combined with Ammonium chloride.]
[L01EX03, pazopanib, The excretion of Mesalazine can be decreased when combined with Pazopanib.]
[L04AA06, mycophenolic acid, Mesalazine may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.]
[N06AA17, amoxapine, The risk or severity of gastrointestinal bleeding can be increased when Amoxapine is combined with Mesalazine.]
[N03AB05, fosphenytoin, The protein binding of Fosphenytoin can be decreased when combined with Mesalazine.]
[C07AA12, nadolol, Mesalazine may decrease the antihypertensive activities of Nadolol.]
[J01CA04, amoxicillin, Mesalazine may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[V03AB15, naloxone, Mesalazine may decrease the excretion rate of Naloxone which could result in a higher serum level.]
[S01GA01, naphazoline, The risk or severity of hypertension can be increased when Mesalazine is combined with Naphazoline.]
[N06BA01, amphetamine, The risk or severity of hypertension can be increased when Amphetamine is combined with Mesalazine.]
[M02AA12, naproxen, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Naproxen.]
[A10BG01, troglitazone, Mesalazine may increase the hypoglycemic activities of Troglitazone.]
[N06AX21, duloxetine, The risk or severity of gastrointestinal bleeding can be increased when Duloxetine is combined with Mesalazine.]
[N04BX01, tolcapone, Mesalazine may decrease the excretion rate of Tolcapone which could result in a higher serum level.]
[S03AA01, neomycin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Neomycin.]
[N01AH06, remifentanil, The risk or severity of hypertension can be increased when Mesalazine is combined with Remifentanil.]
[A10BX02, repaglinide, Mesalazine may increase the hypoglycemic activities of Repaglinide.]
[B01AC17, tirofiban, The risk or severity of bleeding can be increased when Mesalazine is combined with Tirofiban.]
[N05AX14, iloperidone, The risk or severity of hypertension can be increased when Mesalazine is combined with Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Amphotericin B.]
[S01AA19, ampicillin, Mesalazine may decrease the excretion rate of Ampicillin which could result in a higher serum level.]
[L03AX16, plerixafor, Mesalazine may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Netilmicin.]
[N06AX23, desvenlafaxine, The risk or severity of gastrointestinal bleeding can be increased when Desvenlafaxine is combined with Mesalazine.]
[C09CA07, telmisartan, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Mesalazine.]
[J05AB11, valacyclovir, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Valaciclovir.]
[C01CE01, inamrinone, Mesalazine may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[N06AF02, nialamide, The risk or severity of hypertension can be increased when Mesalazine is combined with Nialamide.]
[C08CA04, nicardipine, The therapeutic efficacy of Nicardipine can be decreased when used in combination with Mesalazine.]
[C04AE02, nicergoline, The risk or severity of hypertension can be increased when Mesalazine is combined with Nicergoline.]
[C08CA05, nifedipine, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Nifedipine.]
[M02AA17, niflumic acid, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Niflumic acid.]
[C08CA06, nimodipine, The therapeutic efficacy of Nimodipine can be decreased when used in combination with Mesalazine.]
[C08CA07, nisoldipine, The therapeutic efficacy of Nisoldipine can be decreased when used in combination with Mesalazine.]
[C08CA08, nitrendipine, The therapeutic efficacy of Nitrendipine can be decreased when used in combination with Mesalazine.]
[R07AX01, nitric oxide, Mesalazine may decrease the excretion rate of Nitric Oxide which could result in a higher serum level.]
[J01XE01, nitrofurantoin, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Nitrofurantoin.]
[N05CF03, zaleplon, Mesalazine may decrease the excretion rate of Zaleplon which could result in a higher serum level.]
[N04BC05, pramipexole, Mesalazine may decrease the excretion rate of Pramipexole which could result in a higher serum level.]
[C02DD01, nitroprusside, The therapeutic efficacy of Nitroprusside can be decreased when used in combination with Mesalazine.]
[N01AX13, nitrous oxide, The risk or severity of hypertension can be increased when Mesalazine is combined with Nitrous oxide.]
[C01CA03, norepinephrine, The risk or severity of hypertension can be increased when Mesalazine is combined with Norepinephrine.]
[S01AE02, norfloxacin, Mesalazine may increase the neuroexcitatory activities of Norfloxacin.]
[C02KX01, bosentan, The therapeutic efficacy of Bosentan can be decreased when used in combination with Mesalazine.]
[N06AA10, nortriptyline, The risk or severity of gastrointestinal bleeding can be increased when Nortriptyline is combined with Mesalazine.]
[B01AC16, eptifibatide, The risk or severity of bleeding can be increased when Mesalazine is combined with Eptifibatide.]
[G02CA02, nylidrin, The risk or severity of hypertension can be increased when Mesalazine is combined with Nylidrin.]
[B01AB08, reviparin, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Reviparin.]
[G01AA01, nystatin, The excretion of Mesalazine can be decreased when combined with Nystatin.]
[S02AA16, ofloxacin, Mesalazine may increase the neuroexcitatory activities of Ofloxacin.]
[A02BC01, omeprazole, Omeprazole can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06AA05, opipramol, The risk or severity of gastrointestinal bleeding can be increased when Opipramol is combined with Mesalazine.]
[N02AA02, opium, Mesalazine may decrease the excretion rate of Opium which could result in a higher serum level.]
[R03CB03, metaproterenol, The risk or severity of hypertension can be increased when Mesalazine is combined with Orciprenaline.]
[B01AD07, reteplase, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Reteplase.]
[B01AD09, ancrod, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Ancrod.]
[G04CA02, tamsulosin, Mesalazine may decrease the excretion rate of Tamsulosin which could result in a higher serum level.]
[C01AC01, ouabain, The serum concentration of Ouabain can be decreased when it is combined with Mesalazine.]
[M05BA08, zoledronic acid, The risk or severity of gastrointestinal bleeding can be increased when Mesalazine is combined with Zoledronic acid.]
[J01CF04, oxacillin, Mesalazine may decrease the excretion rate of Oxacillin which could result in a higher serum level.]
[N05BA04, oxazepam, Mesalazine may decrease the excretion rate of Oxazepam which could result in a higher serum level.]
[J01MB05, oxolinic acid, Mesalazine may increase the neuroexcitatory activities of Oxolinic acid.]
[C07AA02, oxprenolol, Mesalazine may decrease the antihypertensive activities of Oxprenolol.]
[C01DX03, oxyfedrine, The risk or severity of hypertension can be increased when Mesalazine is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of hypertension can be increased when Mesalazine is combined with Oxymetazoline.]
[S01BC02, oxyphenbutazone, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Oxyphenbutazone.]
[V04CH30, 4-aminohippuric acid, The excretion of Mesalazine can be decreased when combined with Aminohippuric acid.]
[J04AA01, aminosalicylic acid, The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Mesalazine.]
[N05AH05, asenapine, The therapeutic efficacy of Mesalazine can be decreased when used in combination with Asenapine.]
[B01AB09, danaparoid, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Danaparoid.]
[J04AB30, capreomycin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Capreomycin.]
[H02AB05, paramethasone, The risk or severity of gastrointestinal irritation can be increased when Paramethasone is combined with Mesalazine.]
[C02KC01, pargyline, The therapeutic efficacy of Pargyline can be decreased when used in combination with Mesalazine.]
[A07AA06, paromomycin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Paromomycin.]
[J01MA03, pefloxacin, Mesalazine may increase the neuroexcitatory activities of Pefloxacin.]
[G04BD11, fesoterodine, Mesalazine may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, Mesalazine may decrease the antihypertensive activities of Penbutolol.]
[N05AG03, penfluridol, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Penfluridol.]
[J01CE09, penicillin G procaine, Mesalazine may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N05CA01, pentobarbital, Mesalazine may decrease the excretion rate of Pentobarbital which could result in a higher serum level.]
[L01XX08, pentostatin, Mesalazine may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, The risk or severity of bleeding can be increased when Mesalazine is combined with Pentoxifylline.]
[N04BC02, pergolide, The risk or severity of hypertension can be increased when Mesalazine is combined with Pergolide.]
[C08EX02, perhexiline, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Perhexiline.]
[G04BX06, phenazopyridine, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Phenazopyridine.]
[N06AF03, phenelzine, The risk or severity of hypertension can be increased when Mesalazine is combined with Phenelzine.]
[A10BA01, phenformin, Mesalazine may increase the hypoglycemic activities of Phenformin.]
[B01AA02, phenindione, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Phenindione.]
[C04AX02, phenoxybenzamine, The therapeutic efficacy of Phenoxybenzamine can be decreased when used in combination with Mesalazine.]
[B01AA04, phenprocoumon, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Phenprocoumon.]
[A08AA01, phentermine, The risk or severity of hypertension can be increased when Phentermine is combined with Mesalazine.]
[V03AB36, phentolamine, The therapeutic efficacy of Phentolamine can be decreased when used in combination with Mesalazine.]
[M02AA01, phenylbutazone, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Phenylbutazone.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be increased when Mesalazine is combined with Phenylephrine.]
[A02BC06, dexlansoprazole, Dexlansoprazole can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[R01BA01, phenylpropanolamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Phenylpropanolamine.]
[N03AB02, phenytoin, The serum concentration of Phenytoin can be increased when it is combined with Mesalazine.]
[S01AE05, levofloxacin, Mesalazine may increase the neuroexcitatory activities of Levofloxacin.]
[B02BA01, vitamin K1, Mesalazine may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cidofovir.]
[C08CX01, mibefradil, The therapeutic efficacy of Mibefradil can be decreased when used in combination with Mesalazine.]
[C07AA03, pindolol, Mesalazine may decrease the antihypertensive activities of Pindolol.]
[C10AA05, atorvastatin, The excretion of Mesalazine can be decreased when combined with Atorvastatin.]
[J01CA12, piperacillin, Mesalazine may decrease the excretion rate of Piperacillin which could result in a higher serum level.]
[J05AE01, saquinavir, The excretion of Mesalazine can be decreased when combined with Saquinavir.]
[N06BX03, piracetam, Mesalazine may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Eprosartan is combined with Mesalazine.]
[S01BC06, piroxicam, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Piroxicam.]
[J01DD16, cefditoren, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Cefditoren.]
[J01MA11, grepafloxacin, Mesalazine may increase the neuroexcitatory activities of Grepafloxacin.]
[N02CX01, pizotyline, The risk or severity of hypertension can be increased when Mesalazine is combined with Pizotifen.]
[C09CA04, irbesartan, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Irbesartan is combined with Mesalazine.]
[B01AC13, abciximab, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Abciximab.]
[S01XA13, alteplase, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Alteplase.]
[A10BG02, rosiglitazone, Mesalazine may increase the hypoglycemic activities of Rosiglitazone.]
[S03AA03, polymyxin B, The risk or severity of adverse effects can be increased when Mesalazine is combined with Polymyxin B.]
[C03AA05, polythiazide, The therapeutic efficacy of Polythiazide can be decreased when used in combination with Mesalazine.]
[J05AE03, ritonavir, The excretion of Mesalazine can be decreased when combined with Ritonavir.]
[A10BH03, saxagliptin, Mesalazine may increase the hypoglycemic activities of Saxagliptin.]
[B05XA01, potassium chloride, Potassium chloride may increase the hyperkalemic activities of Mesalazine.]
[V03AB21, potassium iodide, Potassium Iodide may increase the hyperkalemic activities of Mesalazine.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Mesalazine is combined with Insulin lispro.]
[C10AA08, pitavastatin, The excretion of Mesalazine can be decreased when combined with Pitavastatin.]
[C07AB01, practolol, Mesalazine may decrease the antihypertensive activities of Practolol.]
[C02CA01, prazosin, The therapeutic efficacy of Prazosin can be decreased when used in combination with Mesalazine.]
[S03BA02, prednisolone, The risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Mesalazine.]
[H02AB07, prednisone, The risk or severity of gastrointestinal irritation can be increased when Prednisone is combined with Mesalazine.]
[M02AA16, feprazone, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Feprazone.]
[C01DX02, prenylamine, The risk or severity of hyperkalemia can be increased when Mesalazine is combined with Prenylamine.]
[M04AB01, probenecid, Probenecid may decrease the excretion rate of Mesalazine which could result in a higher serum level.]
[C01BA02, procainamide, Mesalazine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[C10AB05, fenofibrate, Mesalazine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[G03DA04, progesterone, The excretion of Mesalazine can be decreased when combined with Progesterone.]
[N05AA03, promazine, The risk or severity of hypertension can be increased when Mesalazine is combined with Promazine.]
[R06AD02, promethazine, The therapeutic efficacy of Mesalazine can be decreased when used in combination with Promethazine.]
[C01BC03, propafenone, Mesalazine may decrease the antihypertensive activities of Propafenone.]
[A03AB05, propantheline, Mesalazine may decrease the excretion rate of Propantheline which could result in a higher serum level.]
[N05AC01, periciazine, The risk or severity of hypertension can be increased when Mesalazine is combined with Periciazine.]
[N05CM06, propiomazine, The risk or severity of hypertension can be increased when Mesalazine is combined with Propiomazine.]
[N01AX10, propofol, The risk or severity of hypertension can be increased when Mesalazine is combined with Propofol.]
[C07AA05, propranolol, Mesalazine may decrease the antihypertensive activities of Propranolol.]
[C01AB01, proscillaridin, The serum concentration of Proscillaridin can be decreased when it is combined with Mesalazine.]
[N02CC04, rizatriptan, The risk or severity of hypertension can be increased when Mesalazine is combined with Rizatriptan.]
[B01AC09, epoprostenol, The risk or severity of bleeding and hemorrhage can be increased when Mesalazine is combined with Epoprostenol.]
[N06AA11, protriptyline, The risk or severity of gastrointestinal bleeding can be increased when Protriptyline is combined with Mesalazine.]
[R01BA02, pseudoephedrine, The risk or severity of hypertension can be increased when Mesalazine is combined with Pseudoephedrine.]
[N05AX12, aripiprazole, The risk or severity of hypertension can be increased when Mesalazine is combined with Aripiprazole.]
[N07XX07, dalfampridine, Mesalazine may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[P02CC01, pyrantel, Mesalazine may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Mesalazine may decrease the excretion rate of Pyrazinamide which could result in a higher serum level.]
[A12BA05, potassium gluconate, Potassium gluconate may increase the hyperkalemic activities of Mesalazine.]
[C01BA01, quinidine, Mesalazine may decrease the excretion rate of Quinidine which could result in a higher serum level.]
[P01BC01, quinine, Mesalazine may increase the hypoglycemic activities of Quinine.]
[A02BA02, ranitidine, Ranitidine can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C02AA01, rescinnamine, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Rescinnamine.]
[C02AA02, reserpine, The therapeutic efficacy of Reserpine can be decreased when used in combination with Mesalazine.]
[J05AP01, ribavirin, Mesalazine may decrease the excretion rate of Ribavirin which could result in a higher serum level.]
[J04AB02, rifampin, The excretion of Mesalazine can be decreased when combined with Rifampicin.]
[R03AC05, rimiterol, The risk or severity of hypertension can be increased when Mesalazine is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of hypertension can be increased when Mesalazine is combined with Ritodrine.]
[J01FA06, roxithromycin, The excretion of Mesalazine can be decreased when combined with Roxithromycin.]
[N02BA05, salicylamide, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Salicylic acid.]
[N05CA06, secobarbital, Mesalazine may decrease the excretion rate of Secobarbital which could result in a higher serum level.]
[N04BD01, selegiline, The risk or severity of hypertension can be increased when Mesalazine is combined with Selegiline.]
[J01GB08, sisomicin, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Sisomicin.]
[A12CD01, sodium fluoride, Mesalazine may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Mesalazine may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, Mesalazine may decrease the antihypertensive activities of Sotalol.]
[L01CD04, cabazitaxel, The excretion of Mesalazine can be decreased when combined with Cabazitaxel.]
[C03DA01, spironolactone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mesalazine is combined with Spironolactone.]
[D07AB02, hydrocortisone butyrate, The risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Mesalazine.]
[C01DA14, isosorbide mononitrate, Mesalazine may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[D10AX03, azelaic acid, Mesalazine may decrease the excretion rate of Azelaic acid which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Tiaprofenic acid.]
[C03CC01, ethacrynic acid, The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Etacrynic acid.]
